论文部分内容阅读
目的在大肠杆菌中表达EBV的早期基因BRLF1,并纯化这个重组蛋白。用纯化的蛋白作为抗原与鼻咽癌(NPC)病人血清中的特异性抗体发生反应,以寻找新的NPC筛检或诊断标志物。方法用表达和纯化的BRLF1基因C端2/3部分蛋白(Rtac2/3)建立间接ELISA方法,检测了59份NPC患者血清中的抗Rta IgG抗体,同时59份健康者血清作对照。结果59份NPC患者血清中50份阳性,而59份健康者对照血清中只有7份阳性。NPC组的阳性率与健康对照组之间差异有统计学意义(P＜0．01)。此方法的灵敏度为84．7％,特异性为88．1％。结论(1)检测人血清中的抗Rta-IgG可以作为NPC诊断的重要标志物之一。(2)如果检测抗Rta-IgG与检测Zebra IgG抗体试验联合使用,用于NPC的筛检和诊断能够进一步提高灵敏度或特异性。
Objective To express the EBV early gene BRLF1 in Escherichia coli and purify the recombinant protein. Purified proteins are used as antigens to react with specific antibodies in the serum of patients with nasopharyngeal carcinoma (NPC) to find new NPC screening or diagnostic markers. Methods The anti-Rta IgG antibody in serum of 59 patients with NPC was detected by indirect ELISA with the expression and purification of the BRLF1 gene C-terminal 2/3 partial protein (Rtac2 / 3), and 59 healthy volunteers were used as controls. Results Fifty-five of 59 NPC patients were positive, while only 7 of 59 healthy controls were positive. The positive rate of NPC group and healthy control group was significantly different (P <0.01). This method has a sensitivity of 84.7% and a specificity of 88.1%. Conclusion (1) The detection of anti-Rta-IgG in human serum can be used as one of the important markers for the diagnosis of NPC. (2) Screening and diagnosis of NPCs can further increase sensitivity or specificity if the test anti-Rta-IgG is used in combination with a test for detecting Zebra IgG antibodies.